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in British Columbia (BC), while controlling for physician case 
volume and rurality of patient residence. 
Methods and Materials: The BC Cancer Registry (BCCR), a 
population-based provincial database, was used to identify all 
patients in BC diagnosed for the first time with a primary non-
thyroid HNC and treated with radiotherapy between 2006 and 
2011. Patient demographics, pathology, stage, treatments, and 
death data were abstracted. Chart review of all patients was 
performed using the British Columbia Cancer Agency Information 
System (CAIS). Patients were categorized as residing in large, 
small and rural local health authorities (LHAs) using BC Stats and 
BC Ministry of Health information. Physician case frequency was 
defined as low (0-14 cases per year), medium (15-29 cases per 
year) and high (> 30 cases per year). We hypothesized that 
survival would not significantly differ among BC cancer centres 
after controlling for rurality, physician case frequency, IMRT use, 
and other patient and tumour characteristics. 
Results: 2330 HNC patients were included in our study. The five-
year head and neck CSS (HNCSS) for the Abbotsford, Fraser 
Valley, Southern Interior, Vancouver and Vancouver Island 
centres was 72%, 71%, 73%, 75% and 68%, respectively (p = 0.54), 
while OS was 59%, 60%, 60%, 65% and 56%, respectively (p = 0.06). 
On multivariable analysis, after controlling for age, gender, 
cancer stage, anatomical site, treatment and physician case 
frequency, neither HNCSS (HR range = 0.92-1.03; p = 0.57-0.91) 
nor OS (HR range = 0.93-1.07; p = 0.47-0.92) was significantly 
different by treatment centre. OS was also not significantly 
different for patients treated by physicians with low case 
frequency (HR = 0.96; 0.77-1.19; p = 0.72) and middle case 
frequency (HR = 1.01; 0.83-1.23; p = 0.91) in reference to high 
case frequency. There was no significant difference in OS among 
patients living in rural LHAs (HR = 0.97; 0.85-1.11; p = 0.67) and 
small LHAs (HR = 1.13; 0.86-1.47; p = 0.38) in reference to large 
LHAs. 
Conclusions: There was no significant difference in survival 
among British Columbia Cancer Agency treatment centres after 
controlling for differences in rurality, physician case volume and 
other potential confounding variables. 
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Purpose: Lymph node density (LND, number of positive lymph 
nodes/total number of excised lymph nodes) has been shown to 
be associated with outcomes in multiple malignancies. In this 
study, the impact of LND on distant metastasis (DM) and overall 
survival (OS) in oral cavity squamous cell carcinoma (OSCC) was 
investigated. 
Methods and Materials: Retrospective review of pN0-2 OSCC 
patients treated between 1994-2012 with curative surgery with 
neck dissection (ND) +/- post-operative radiotherapy (PORT) with 
or without concurrent chemotherapy (CCT). LND was subjected 
to multivariable analysis (MVA) of DM and OS, adjusted for pT3-
4 category, extracapsular extension (ECE), high histological 
Grade (G3), lymphovascular invasion (LVI), perineural invasion 
(PNI), and tumour subsite. 
Results: Overall 914 patients were identified; median age: 61 
years (18-92); median follow up: 51 months (1–189); pT3-4: 283 
(31%); pN-classification: N0: 482 (53%), N1: 128 (14%), N2a: 6 
(0.5%); N2b: 225 (24.5%); N2c: 73 (8%); median number of 
dissected nodes: 36 (6-125); median number of pN+: 2 (1-49); 
median LND for pN+ patients: 0.06; ECE: 187 (20%); G3: 147 
(16%); LVI: 115 (13%); PNI: 416 (46%). Bilateral ND was performed 
in 367 (40%); PORT was used in 452 (49%); and CCT in 80 (9%). 
The five-year distant control (DC) and OS were 89% and 70%; 
respectively. pT3-4 (p < 0.001), G3 (p < 0.001), LVI (p = 0.0013), 
and PNI (p < 0.001) were all associated with high LND. On MVA, 
LND > 0.06 was associated with more DM (HR = 1.8; 95%CI = 1.1-
3.1; p = 0.017) and lower OS (HR = 2; 95%CI = 1.4–2.8; p < 0.001). 
In subgroup analysis of pN2 patients (n = 304): higher LND (> 0.14) 
was associated with lower five-year DC (67%, p = 0.014) and OS 
(25%, p < 0.001), and on MVA within the pN2 subgroup, both 
higher LND (p < 0.001) and ECE (p = 0.006) were associated with 
lower OS. 
Conclusions: High LND is associated with higher rate of DM and 
lower OS in OSCC. LND should be assessed in pN2 patients in 
future prospective trials to select patients for adjuvant 
therapies.  
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Purpose: Modern radiation therapy (RT) techniques offer precise 
delivery to the defined targets in head and neck cancer (HNC) 
while respecting surrounding critical organ tolerances. This is 
due in part to the enhanced ability to define the gross tumour 
volume (GTV) with supplemental imaging such as MRI and PET 
scans. As a standard, a high dose clinical target volume (CTV) of 
5 mm is added to the GTV to further ensure complete coverage 
of gross disease. However, HN tumours often shrink during RT, 
which suggests that the high dose CTV margin during treatment 
may be greater than the original 5 mm, thus leading to 
overdosage of normal tissues. This study intends to quantify the 
potential gain of an adaptive technique that maintains the CTV 
to a changing gross tumour volumes in a series of HNC patients 
treated with chemoradiotherapy. 
Methods and Materials: A prospective study in 2009 enrolled 
advanced HNC patients undergoing curative IMRT to receive a 
dynamic pre-treatment FDG PET-CT simulator scan, which was 
also repeated intratreatment (IT) between the 10th and 15th 
fraction. Fifty-two patients were evaluated. Two radiation 
oncologists separately contoured GTVs in the pre- and IT scans 
to account for inter-observer variability. Rigid fusion of the 
planning CT to pre- and IT PET-CT scans was performed. Margin 
expansions ranging from 1-25 mm were performed on the pre-
treatment GTV to volumetrically match the original CTV (as 
defined by the treating radiation oncologist), based on optimal 
Dice Similarity Indices (DSI). An identical process took place with 
the IT PET CT scan, where the IT GTV margins were expanded to 
the original treatment CTV. 
Results: Fifty-two patients were evaluated with a total of 152 
targets (50 primaries and 102 LNs). Volume matching given by 
DSI showed that the pre-treatment GTV needed an average 7.22 
± 4.75 mm expansion to optimally match the clinical CTV while 
the IT GTV required a margin of 8.27 ± 4.18 mm. On average, the 
radial size of the primary CTV decreased by 1.05 ± 3.59 mm 
between pre- and IT scans but 17 patients (32.7%) had a 
shrinkage over 5 mm and six patients (11.5%) had tumour growth 
of more than 5 mm. Nineteen patients had a paradoxical 
response between the primary and the LNs. On multivariate 
analysis, after controlling for smoking history, HPV status and 
stage, non-smokers only showed significant shrinkage in both 
primaries (mean = 2.34 ± 0.64, p = 0.0004) and LNs (mean = 2.521 
± 0.92, p = 0.008). In total, primaries and LNs had similar 
outcome with a mean of 1.14 ± 3.99 mm and 0.67 ± 3.63 mm 
respectively (p = 0.54). 
Conclusions: Our results show that HNC tumour shrinkage during 
RT is highly variable. A subset of patients is highly responsive to 
treatment where an adaptive approach to reduce treatment 
margins (CTV) may reduce normal tissue toxicities. Non-smokers 
respond better than smokers while HPV-positive patients don’t 
seem to have an early response at two to three weeks. 
 
